View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
March 26, 2019updated 27 Mar 2019 3:54pm

North America’s pharma industry sees a rise of 1% in deal activity in Q4 2018

North America’s pharma industry saw a rise of 1% in overall deal activity during Q4 2018, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 264 deals worth $16.65bn were announced for the region during Q4 2018, against the four-quarter average of 261 deals.

Of all the deal types, venture financing saw most activity in Q4 2018 with 166, representing a 62.9% share for the region.

In second place was M&A with 79 deals, followed by private equity deals with 19 transactions, respectively capturing a 29.9% and 7.2% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in North America’s pharma industry with $12.53bn, while venture financing and private equity deals totalled $3.53bn and $587.85m, respectively.

North America pharma industry deals in Q4 2018: Top deals

The top five pharma deals accounted for 64.9% of the overall value during Q4 2018.

The combined value of the top five pharma deals stood at $10.8bn, against the overall value of $16.65bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.

In second place was the $2.1bn acquisition of Endocyte by Novartis and in third place was Swedish Orphan Biovitrum’s $1.97bn asset transaction with AstraZeneca.

The $1.2bn acquisition of Pacific Biosciences of California by Illumina and AMAG Pharmaceuticals and Magellan Merger Sub’s acquisition of Perosphere Pharmaceuticals for $433.2m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology